Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | CLK2 | P49760 | 1/20 | 0.66 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8156650 | 1.00 | KCNH2 (0.68) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL8129298 | 0.91 | KCNH2 (0.58) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| Ammonia Solution, Strong SCHEMBL8131738 | 0.90 | KCNH2 (0.57) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL8134406 | 0.87 | KCNH2 (0.68) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL8133566 | 0.87 | KCNH2 (0.68) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| Monoethanolamine SCHEMBL8134338 | 0.86 | KCNH2 (0.56) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL8136907 | 0.86 | KCNH2 (0.70) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL9292875 | 0.85 | KCNH2 (0.67) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL9773824 | 0.84 | KCNH2 (0.79) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL9293428 | 0.84 | KCNH2 (0.53) | KCNH2KDM4EALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KCNH2 1025/4885KDM4E 2452/4885ALDH1A1 2174/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KCNH2 1715/4885KDM4E 3249/4885ALDH1A1 3977/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | KCNH2 1715/4885KDM4E 3249/4885ALDH1A1 3977/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KCNH2 1699/4885KDM4E 3157/4885ALDH1A1 3889/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | KCNH2 1699/4885KDM4E 3157/4885ALDH1A1 3889/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KCNH2 1699/4885KDM4E 3157/4885ALDH1A1 3889/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | KCNH2 726/4885KDM4E 2021/4885ALDH1A1 2305/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KCNH2 1112/4885KDM4E 2466/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.